Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;55(8):705-717.
doi: 10.4070/kcj.2024.0354. Epub 2025 Apr 11.

Prognostic Value of Plasma Big Endothelin-1 in Patients Hospitalized for Heart Failure

Affiliations

Prognostic Value of Plasma Big Endothelin-1 in Patients Hospitalized for Heart Failure

Jinxi Wang et al. Korean Circ J. 2025 Aug.

Abstract

Background and objectives: Endothelin-1 (ET-1) is a potent vasoconstrictor and multifunctional neuroendocrine hormone that is closely associated with the pathophysiology of heart failure (HF). Currently, the evidence about the predictive value of big ET-1 in HF remains insufficient. This study aims to investigate the prognostic importance of big ET-1 in HF.

Methods: We examined the incidence of cardiovascular death in a single-center retrospective cohort of HF (de novo, worsening, or chronic included).

Results: The 4,368 hospitalized HF patients were enrolled. During the median follow-up of 875 (365-1,400) days, 851 (19.5%) patients had primary outcome events. Big ET-1 was independently associated with cardiovascular death as a continuous variable (hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.06-1.21; p<0.001) and by tertiles (HR, 1.35; 95% CI, 1.06-1.72; p=0.017 for tertile 2 and HR, 1.70; 95% CI, 1.32-2.19; p<0.001 for tertile 3). This pattern of risk was maintained after further adjustment for NT-proBNP (HR, 1.11; 95% CI, 1.03-1.19; p=0.006 for continuous variable, HR, 1.30; 95% CI, 1.02-1.67; p=0.035 for tertile 2, and HR, 1.69; 95% CI, 1.23-2.05; p=0.034 for tertile 3). Net reclassification index (NRI) and integrated discrimination improvement (IDI) analysis showed that big ET-1 provided additional predictive power in combination with NT-proBNP (NRI, 0.11; 95% CI, 0.04-0.17; p=0.012 and IDI, 0.012; 95% CI, 0.003-0.017; p<0.001).

Conclusions: Elevated big ET-1 was independently associated with cardiovascular death in patients with HF. Big ET-1 may be a promising indicator of HF prognosis. In combination with NT-proBNP, big ET-1 may provide incremental predictive information.

Keywords: Big endothelin-1; Biomarkers; Heart failure; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest.

Figures

Figure 1
Figure 1. Kaplan-Meier curves of cardiovascular death and secondary outcomes stratified by baseline big endothelin-1 tertile.
(A) Cardiovascular death, (B) HHF, and (C) all-cause mortality. HHF = hospitalization for heart failure.
Figure 2
Figure 2. Association between baseline big ET-1 as a continuous variable and unadjusted risk of cardiovascular death by restricted cubic splines.
CI = confidence interval; ET-1 = endothelin-1; HR = hazard ratio.
Figure 3
Figure 3. The time-dependent ROC curves of big ET-1 and NT-proBNP in predicting the primary outcome of heart failure.
AUC = area under the curve; ET-1 = endothelin-1; NT-proBNP = N-terminal pro-B-type natriuretic peptide; ROC, receiver operating characteristic.
Figure 4
Figure 4. Event rates of cardiovascular death and all-cause mortality according to baseline big ET-1 tertile and NT-proBNP tertile.
(A) Cardiovascular death and (B) all-cause mortality. CI = confidence interval; ET-1 = endothelin-1; HR = hazard ratio; NT-proBNP = N-terminal pro-B-type natriuretic peptide; T = tertile.

Similar articles

Cited by

References

    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858. - PMC - PubMed
    1. Levin ER. Endothelins. N Engl J Med. 1995;333:356–363. - PubMed
    1. Barton M, Yanagisawa M. Endothelin: 30 years from discovery to therapy. Hypertension. 2019;74:1232–1265. - PubMed
    1. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev. 2016;68:357–418. - PMC - PubMed
    1. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504–509. - PubMed